List of Implants Companies in New Jersey - 11

Avertix is committed to advancing life-sustaining patient care and the long-term management of Advanced Cardiovascular Disease through innovation, clinical science, and collaboration. With FDA-approved labeling indicating the Guardian System is safe and effective, we're dedicated to providing physicians, health systems, and allied health professionals with the Avertix Guardian to help advance the standard of patient care. Avertix's Guardian™ is the first implantable, patient alerting system designed to warn patients to seek medical attention for Acute Coronary Syndrome (ACS), including silent heart attacks. Delays in treatment contribute to the high level of mortality and morbidity from heart attacks. Symptoms (such as chest pain) are a poor predictor of ACS events with less than 20% of patients presenting to the emergency room actually having a true positive ACS event and more than one-third of heart attacks having atypical or no symptoms.

Avertix is committed to advancing life-sustaining patient care and the long-term management of Advanced Cardiovascular Disease through innovation, clinical science, and collaboration. With FDA-approved labeling indicating the Guardian System is safe and effective, we’re dedicated to providing physicians, health systems, and allied health professionals with the Avertix Guardian to help advance the standard of patient care. Avertix’s Guardian™ is the first implantable, patient alerting system designed to warn patients to seek medical attention for Acute Coronary Syndrome (ACS), including silent heart attacks. Delays in treatment contribute to the high level of mortality and morbidity from heart attacks. Symptoms (such as chest pain) are a poor predictor of ACS events with less than 20% of patients presenting to the emergency room actually having a true positive ACS event and more than one-third of heart attacks having atypical or no symptoms.

Bionex’s mission is to realize the applications of bio-pharmaceutical and life sciences into commercial products and services that benefit human health. Strategically, Bionex engages in two areas of business activities. First, Bionex offers contract R&D services, from early-stage concept development, cGMP clinical supply manufacturing to full-scale commercialization, for bio-pharmaceutical products. Second, Bionex develops and out-licenses its own proprietary formulations, drug delivery technologies, and products related to medical, health food, and skin-care applications. Our expertise is focused on transdermal and transmucosal drug systems. We adopt a science-based, and yet pragmatic and out-of-box approach which often leads to fruitful outcomes, in time- and cost-effective manner. Bionex capabilities are its expertise in formulation science and analytical chemistry, full range of formulation/processing, analytical, and testing capabilities in cGMP facility, and well-connected network of industrial, academic and business consultants and advisors. Many of our in-house innovation R&D projects are funded by National Institute of Health (NIH), National Science Foundation (NSF), state grants and non-for-profit organizations.

At Glucotrack, we are pioneers in diabetes technology, dedicated to transforming the way diabetes is managed. Our mission is to develop innovative, long-term solutions that prioritize accuracy and ease of use. With a commitment to reducing the daily burden of diabetes management, we create cutting-edge technologies designed to enhance the lives of those we serve. Join us in our journey towards a future where managing diabetes is simpler, more effective, and empowering.

Impulse Dynamics is a fast-growing medical device company that has pioneered a new form of therapy for heart failure called Cardiac Contractility Modulation, or CCM. The Optimizer Smart is the first implantable device for the treatment of chronic heart failure in patients with normal QRS durations.

Genomic Prediction provides advanced genomic tests which improve IVF health outcomes. Genomic Prediction Inc. (GP) was incorporated in Delaware, May 1, 2017. The research insights which led to the creation of GP stretch back much further. Research and data exchange agreements to develop molecular methodology, signed with some of the largest biotechnology vendors in the world, were ongoing as early as 2015. In the decade prior, the founders’ work in embryology, detection of chromosomal abnormality, computational genomics, algorithms, and polygenic architecture led to GP’s superior and innovative methodology for the genetic testing of human embryos. GP’s products incorporate fundamental improvements on existing methods. GP offers IVF parents a cost-effective means to evaluate genetic risk due to chromosomal abnormality (ploidy), single-gene mutations, and polygenic diseases. Accurate understanding of the genomic architecture of human disease requires larger training datasets, greater accuracy, and a more rigorous, empirical basis of computational modeling (machine learning) than implemented in the past with simpler technologies and simpler computational methods. GP represents the next step in embryo genetic testing, combining dense, genome-wide genotyping methods with sophisticated validation-focused modeling, suitable for the information age.

NovoPedics, Inc. is developing implantable medical devices designed to relieve pain and restore mobility to patients suffering from severe meniscal injuries and meniscectomies. MeniscoFix™ is a polymer fiber-reinforced scaffold for total meniscus replacement designed to be gradually resorbed by the body and be replaced by new tissue. It represents an innovative approach to replace damaged meniscal tissue with a patented fiber-reinforced design similar to the native meniscus. It is designed to be attached to both soft tissue and bone, thus potentially enabling its use in total meniscus replacement surgery.

Onkos Surgical is a privately held, specialty medtech company founded in 2015 that uses a digital platform and patient imaging analysis, to reconstruct bones following cancer therapy using personalized surgical planning and 3D printing.

Orthobond is an antimicrobial technology company that has developed proprietary antimicrobial nanosurfaces, with broad applications in the medical device industry and more such as commercial, industrial, automotive, and beyond. We’re the first company to utilize nanoscale surface modifications that can be permanently bound to any surface, killing bacteria, viruses, and fungi by mechanically rupturing pathogens without using antibiotics.

Samsara Vision, Inc. is a privately held specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary implantable ophthalmic devices and technologies that are intended to significantly improve vision and quality of life for individuals with untreatable retinal disorders. Our lead product, the Implantable Miniature Telescope (by Dr. Isaac Lipshitz), is the first FDA-approved implantable medical device demonstrated to improve vision and quality of life in individuals with the most advanced, irreversible form of age-related macular degeneration (AMD) – End-Stage AMD. End-Stage AMD is the leading cause of blindness in older Americans. Our goal is to help patients reconnect to the things in life they love to see and do. To help achieve this, we will establish a high level of collaboration with our healthcare provider customers through a broad range of direct support programs and services.

Vascular Therapies is a biotechnology company focused on improving patient outcomes by reducing surgical stenosis in patients with kidney and vascular disease. The company has developed Sirogen™, an investigational sirolimus formulation for local, perivascular drug delivery. Sirogen™ is currently undergoing clinical trials to determine its safety and effectiveness in improving vascular access outcomes in patients requiring an arteriovenous fistula for hemodialysis.